AMGN – Amgen Inc.
Amgen Inc.AMGN
$277.13Name : Amgen Inc.
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $149,014,462,464.00
EPSttm : 10.97
Amgen Inc.
$277.13
0.71%$1.98Float Short %
2.47
Margin Of Safety %
13
Put/Call OI Ratio
1.06
EPS Next Q Diff
0.48
EPS Last/This Y
13.23
EPS This/Next Y
0.65
Price
277.22
Target Price
316.39
Analyst Recom
2.21
Performance Q
-9.37
Relative Volume
0.91
Beta
0.49
Ticker: AMGN
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-06-02 | AMGN | 288.5 | 0.82 | 0.85 | 162299 |
| 2025-06-03 | AMGN | 289.58 | 0.83 | 0.40 | 166217 |
| 2025-06-04 | AMGN | 287.03 | 0.83 | 3.66 | 171147 |
| 2025-06-05 | AMGN | 287.12 | 0.86 | 0.95 | 175249 |
| 2025-06-06 | AMGN | 290.35 | 0.87 | 1.09 | 176732 |
| 2025-06-09 | AMGN | 289.97 | 0.86 | 0.70 | 172341 |
| 2025-06-10 | AMGN | 293.39 | 0.88 | 1.83 | 176633 |
| 2025-06-11 | AMGN | 291.84 | 0.90 | 0.71 | 180690 |
| 2025-06-12 | AMGN | 297.32 | 0.91 | 1.48 | 181418 |
| 2025-06-13 | AMGN | 295.22 | 0.91 | 0.38 | 183367 |
| 2025-06-16 | AMGN | 295.08 | 0.88 | 0.74 | 179622 |
| 2025-06-17 | AMGN | 289.98 | 0.88 | 0.86 | 181625 |
| 2025-06-18 | AMGN | 289.5 | 0.89 | 0.76 | 184132 |
| 2025-06-20 | AMGN | 289.4 | 0.90 | 1.44 | 185775 |
| 2025-06-23 | AMGN | 272.55 | 1.12 | 0.82 | 141036 |
| 2025-06-24 | AMGN | 277.01 | 1.10 | 0.83 | 150420 |
| 2025-06-25 | AMGN | 280.46 | 1.09 | 0.58 | 154288 |
| 2025-06-26 | AMGN | 279.03 | 1.06 | 0.88 | 157749 |
| 2025-06-27 | AMGN | 277.18 | 1.06 | 0.71 | 159021 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-06-02 | AMGN | 288.50 | 5.3 | 5915.2 | 20.84 |
| 2025-06-03 | AMGN | 289.57 | 5.3 | 5947.3 | 20.84 |
| 2025-06-04 | AMGN | 286.97 | 5.3 | 5795.1 | 20.84 |
| 2025-06-05 | AMGN | 287.10 | 5.3 | 5905.7 | 20.84 |
| 2025-06-06 | AMGN | 290.50 | 5.3 | 6062.8 | 20.84 |
| 2025-06-09 | AMGN | 289.98 | 5.3 | 5907.6 | 20.84 |
| 2025-06-10 | AMGN | 293.47 | 5.3 | 6065.4 | 20.84 |
| 2025-06-11 | AMGN | 291.83 | 5.3 | 5856.6 | 20.84 |
| 2025-06-12 | AMGN | 297.29 | 5.3 | 6146.1 | 20.84 |
| 2025-06-13 | AMGN | 295.17 | 5.3 | 5836.5 | 20.84 |
| 2025-06-16 | AMGN | 295.48 | 5.3 | 5932.4 | 20.84 |
| 2025-06-17 | AMGN | 290.01 | 5.3 | 5697.2 | 20.84 |
| 2025-06-18 | AMGN | 289.63 | 5.3 | 5904.6 | 20.84 |
| 2025-06-20 | AMGN | 289.33 | 5.3 | 5909.6 | 20.84 |
| 2025-06-23 | AMGN | 272.36 | 5.3 | 5223.5 | 20.84 |
| 2025-06-24 | AMGN | 277.54 | 5.3 | 6141.6 | 20.84 |
| 2025-06-25 | AMGN | 280.46 | 5.3 | 6048.1 | 20.84 |
| 2025-06-26 | AMGN | 279.09 | 5.3 | 5864.2 | 20.85 |
| 2025-06-27 | AMGN | 277.22 | 5.3 | 5842.0 | 20.85 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-06-02 | AMGN | -6.41 | 2.37 | 2.68 |
| 2025-06-03 | AMGN | -6.41 | 2.37 | 2.68 |
| 2025-06-04 | AMGN | -6.41 | 2.37 | 2.68 |
| 2025-06-05 | AMGN | -6.41 | 2.37 | 2.68 |
| 2025-06-06 | AMGN | -6.41 | 2.37 | 2.68 |
| 2025-06-09 | AMGN | -6.53 | 2.37 | 2.68 |
| 2025-06-10 | AMGN | -6.53 | 2.37 | 2.68 |
| 2025-06-11 | AMGN | -6.53 | 2.37 | 2.41 |
| 2025-06-12 | AMGN | -6.53 | 2.37 | 2.41 |
| 2025-06-13 | AMGN | -6.53 | 2.37 | 2.41 |
| 2025-06-16 | AMGN | -6.53 | 2.64 | 2.41 |
| 2025-06-18 | AMGN | -6.53 | 2.64 | 2.41 |
| 2025-06-20 | AMGN | -6.53 | 2.64 | 2.41 |
| 2025-06-23 | AMGN | -6.53 | 2.99 | 2.41 |
| 2025-06-24 | AMGN | -6.53 | 2.99 | 2.41 |
| 2025-06-25 | AMGN | -6.53 | 2.99 | 2.41 |
| 2025-06-26 | AMGN | -6.53 | 2.99 | 2.47 |
| 2025-06-27 | AMGN | -6.53 | 2.99 | 2.47 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
4.9
Avg. EPS Est. Current Quarter
5.23
Avg. EPS Est. Next Quarter
5.38
Insider Transactions
-6.53
Institutional Transactions
2.99
Beta
0.49
Average Sales Estimate Current Quarter
8860
Average Sales Estimate Next Quarter
8922
Fair Value
314.01
Quality Score
85
Growth Score
90
Sentiment Score
9
Actual DrawDown %
20.1
Max Drawdown 5-Year %
-24.9
Target Price
316.39
P/E
25.3
Forward P/E
12.88
PEG
5.72
P/S
4.39
P/B
24.01
P/Free Cash Flow
13.65
EPS
10.95
Average EPS Est. Cur. Y
20.85
EPS Next Y. (Est.)
21.49
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
17.49
Relative Volume
0.91
Return on Equity vs Sector %
71.7
Return on Equity vs Industry %
63.4
EPS 1 7Days Diff
EPS 1 30Days Diff
0.01
EBIT Estimation
5842
Amgen Inc.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 28000
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
stock quote shares AMGN – Amgen Inc. Stock Price stock today
news today AMGN – Amgen Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch AMGN – Amgen Inc. yahoo finance google finance
stock history AMGN – Amgen Inc. invest stock market
stock prices AMGN premarket after hours
ticker AMGN fair value insiders trading